Information about GlobalPharmacyMeds.to
List of countries where we can ship Paliperidone:
Latest news releases on Paliperidone:
Paliperidone palmitate long-acting injection compared to risperidone for schizophrenia; When flexibly dosed every four weeks, paliperidone palmitate appears comparable in efficacy and tolerability to risperidone.
Paliperidone: learn about side effects, dosage, special precautions, and more on MedlinePlus
Physician reviewed paliperidone (oral) patient information - includes paliperidone description, dosage and directions.
INVEGA ® (paliperidone) extended-release tablets are indicated for the treatment of schizophrenia in adults and adolescents (12-17 years of age). The efficacy of INVEGA ® in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (12-17 years of age), as well as one maintenance trial in adults.
You are viewing Paliperidone, Serum/Plasma Test (4113SP) *Rejection criteria pertain to clinical specimen submissions only. **Stated minimum volume allows for a single analysis.
Contraindications: Paliperidone is contraindicated in patients with a known hypersensitivity to paliperidone, risperidone, or to any excipients in INVEGA ®. Cerebrovascular Adverse Events (CAEs): CAEs (eg, stroke, transient ischemia attacks), including fatalities, were reported in placebo-controlled trials in elderly patients with dementia ...
Find information for health care professionals about INVEGA® SUSTENNA®. See full safety and Prescribing Information, including boxed WARNING.
Product details for Invega; Name: Invega: Agency product number: EMEA/H/C/000746: Active substance: paliperidone. International non-proprietary name (INN) or common name
Invega 3 mg prolonged-release tablets - Summary of Product Characteristics (SmPC) by Janssen-Cilag Ltd
175 mg prolonged release suspension for injection. Each pre-filled syringe contains 273 mg paliperidone palmitate equivalent to 175 mg paliperidone.